The Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures, offering a structured view of how this preclinical-stage biotechnology company reports its progress and corporate events. Telomir’s filings show that it is a Florida corporation with common stock listed on The Nasdaq Stock Market LLC under the symbol TELO, and they document its focus on developing Telomir-1, a small-molecule therapy targeting epigenetic and metabolic mechanisms in cancer and age-related disease.
For Telomir, Form 8‑K current reports are especially informative. Recent 8‑Ks include Item 8.01 disclosures of new preclinical data, such as Telomir-1’s effects on PSA levels in prostate cancer cells, tumor growth and metastasis in triple-negative breast cancer models, cytotoxicity in leukemia cells, and reductions in intracellular iron compared with the iron chelator Deferoxamine. Another 8‑K details completion of GLP toxicology and safety pharmacology studies in rat and dog models, noting that Telomir-1 was generally well tolerated with no treatment-related adverse or dose-limiting toxicities observed.
Filings also cover corporate and governance matters. Examples include an 8‑K describing a director resignation, compensation committee actions regarding the chief executive officer’s incentives, and a Nasdaq notice related to the timing of the company’s annual shareholder meeting under Listing Rule 5620(a). An additional 8‑K outlines a binding Letter of Intent to acquire TELI Pharmaceuticals, Inc., intended to consolidate worldwide intellectual property and development rights to Telomir-1 within a single public company structure.
On Stock Titan, these filings are supplemented by AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand the implications of GLP safety data, oncology study updates, compensation decisions, and Nasdaq communications. Users can review real-time updates from EDGAR, examine narrative descriptions of Telomir-1’s preclinical profile, and track how Telomir reports its IND-enabling activities and strategic transactions over time.
Telomir Pharmaceuticals, Inc. (TELO) reported new peer-reviewed preclinical data showing that its small molecule Telomir-Zn improved visual function and preserved retinal structure in a zebrafish model of age-related macular degeneration. After 14 days of oral dosing, Telomir-Zn enhanced several measures of visual performance and reduced retinal degeneration, with restoration of thickness across multiple retinal layers.
The study also found that Telomir-Zn reduced mitochondrial oxidative stress, increased intracellular zinc, lowered labile intracellular iron and potently inhibited multiple Fe²⁺-dependent Jumonji C histone demethylases, supporting a metal-dependent epigenetic mechanism. Relative telomeric DNA content and selected aging-associated DNA methylation patterns shifted toward a healthier profile. Despite these retinal findings, clinical development remains focused on oncology, with Telomir-Zn advancing under an FDA-cleared Phase 1/2 trial in advanced or metastatic triple-negative breast cancer.
Telomir Pharmaceuticals, Inc. (TELO) reported the results of its 2026 Annual Meeting of Stockholders held on September 11, 2026. Stockholders owning 47,129,480 shares, or 68.53% of the 68,774,954 shares outstanding as of the July 21, 2026 record date, were represented, constituting a quorum.
All three proposals were approved, including the election of directors Erez Aminov, Matthew Whalen, Edward MacPherson and Matthew Del Giudice, M.D. For example, Aminov received 43,363,662 votes for and 93,927 withheld, with 3,671,891 broker non-votes. Stockholders also ratified Salberg & Company, P.A. as independent registered public accounting firm for 2026 with 46,998,583 votes for, and approved a possible adjournment of the meeting with 44,841,042 votes for.
Telomir Pharmaceuticals, Inc. (TELO) reported new preclinical data showing that its lead candidate Telomir-Zn inhibited cell growth in both human and canine osteosarcoma cell lines (HOS, D17, Abrams) at similar low concentrations. These in‑vitro findings support further translational work in osteosarcoma.
The company’s primary clinical effort remains a Phase 1/2 program of Telomir-Zn in advanced or metastatic triple-negative breast cancer
Telomir Pharmaceuticals, Inc. is the subject of an amended beneficial ownership report by John Paul DeJoria, acting both as trustee of the John Paul DeJoria Family Trust and in his individual capacity. He reports beneficial ownership of 3,554,871 shares of Telomir common stock. This represents 5.169% of the common stock, based on 68,774,956 shares outstanding as of August 13, 2026, as referenced from Telomir’s quarterly report. DeJoria has sole voting and dispositive power over all 3,554,871 shares and no shared voting or dispositive power.
Telomir Pharmaceuticals, Inc. reported a net loss of $1.7 million for the quarter and $2.7 million for the six months ended June 30, 2026, with no revenue as it remains a clinical-stage oncology company focused on its lead candidate Telomir-Zn. Cash was $5.2 million and stockholders’ equity $5.0 million, down from $7.3 million of cash and $5.9 million of equity at December 31, 2025.
Management discloses that these cash resources, combined with ongoing losses and expected spending, raise substantial doubt about the company’s ability to continue as a going concern over the 12 months following issuance, and additional external financing is needed to fund operations and clinical trials. Telomir completed a related-party merger with TELI Pharmaceuticals on April 22, 2026, issuing 34,389,710 shares of common stock to acquire worldwide intellectual property rights to Telomir-Zn; because the acquired net assets had a historical carrying value of zero apart from a $1.0 million cash contribution, the transaction generated a $46.1 million deemed dividend and roughly doubled shares outstanding to 68,774,956.
Operating expenses decreased sharply year over year, with general and administrative costs for the first half of 2026 falling to $1.9 million from $6.9 million, largely due to lower stock-based compensation, while research and development rose to $0.9 million as Telomir-Zn advanced. The company has FDA clearance of an Investigational New Drug application for a trial in advanced or metastatic triple-negative breast cancer and has a binding related-party funding commitment of up to $4.0 million tied to future Telomir-Zn regulatory and clinical milestones, alongside an unused $5.0 million related-party credit line.
Telomir Pharmaceuticals, Inc. reported that a peer-reviewed preclinical study of its lead candidate Telomir-Zn was published in the Journal of Oncology Research and Therapy, Volume 11, Issue 3. The study shows Telomir-Zn depletes intracellular iron to inhibit JmjC histone demethylases (KDMs), enzymes overexpressed in aggressive cancers, leading to tumor-suppressor gene reactivation and reduced tumor growth in prostate and triple-negative breast cancer (TNBC) models.
In TNBC models, Telomir-Zn reduced primary tumor size and significantly curtailed metastatic spread in an HCC1806 model, and showed synergistic tumor reduction when combined with paclitaxel in BT-549 xenografts, while one TNBC model (MDA-MB-231) did not respond. The compound killed iron-dependent TNBC cells at low concentrations while sparing normal cells at concentrations more than 50-fold higher, suggesting a favorable selectivity window. These findings support advancement of Telomir-Zn into a planned Phase 1/2 clinical trial in TNBC under an active IND.
Telomir Pharmaceuticals, Inc. is asking shareholders to vote at a virtual-only annual meeting on September 11, 2026, at 11:00 a.m. Eastern Time. Holders of 68,774,954 shares of common stock as of July 21, 2026 may vote; a quorum requires holders of 33.33% of outstanding shares present in person or by proxy.
Shareholders will vote on three items: electing four directors (including CEO and Chair Erez Aminov), ratifying Salberg & Company, P.A. as independent auditor for 2026, and approving a possible adjournment to solicit additional proxies. The Board recommends voting FOR all proposals. The proxy also details 2025 executive pay, with Mr. Aminov receiving total compensation of $4,880,350, a base salary increase to $500,000 effective January 1, 2026, and option repricing on 3,960,170 shares to an exercise price of $1.30. An equity incentive plan reserves 11,500,000 shares, and major holders include Brian McNulty at 26.93% and Mr. Aminov at 16.10% of common stock.
Telomir Pharmaceuticals director Whalen Matthew Pratt received a grant of 50,000 Non-Qualified Stock Options on April 16, 2026. The options have an exercise price of $1.3400 per share, expire on April 16, 2036, were granted under the 2023 Omnibus Incentive Plan, vested immediately, and leave him holding 50,000 derivative securities directly.
Telomir Pharmaceuticals, Inc. reported that director Edward Clouston MacPherson received a grant of 50,000 non-qualified stock options on April 16, 2026. The options have an exercise price of $1.34 per share, vested immediately, expire on April 16, 2036, and represent 50,000 options held directly after the grant.
Telomir Pharmaceuticals, Inc. reported that director Matthew Paul Del Giudice received a grant of 50,000 non-qualified stock options on April 16, 2026. The options have an exercise price of $1.34 per share, equal to the closing price that day, and vested immediately upon issuance. They are exercisable for common stock and expire on April 16, 2036, resulting in Del Giudice holding 50,000 options after the grant, awarded under the company’s 2023 Omnibus Incentive Plan. The transaction was not made under a Rule 10b5-1 trading plan.